Morning Wire FDA Delays Covid Therapeutics | December 17, 2021
Dec 17, 2021
The FDA has delayed approval for a promising COVID therapeutic, causing public frustration. In California, rising crime rates spark backlash against progressive policies, with troubling statistics revealing the impact. Law enforcement insights highlight the challenges of crime control amid changing public sentiment. Additionally, new measures targeting forced labor in China create complications for U.S. companies, illustrating the complex intersection of domestic and international policies.
AI Snips
Chapters
Transcript
Episode notes
Paxlovid's Effectiveness and FDA Delay
- Pfizer's Paxlovid drastically reduces COVID deaths.
- The FDA hasn't scheduled a review, delaying its availability.
Fluvoxamine as COVID Treatment
- Fluvoxamine, an antidepressant, may effectively treat COVID-19.
- This cheap, off-patent drug is less discussed than newer, more expensive options.
California's Rising Crime
- California's rising crime is linked to soft-on-crime policies by DAs.
- Policies like no cash bail contribute to increased crime rates in cities like Los Angeles.